Abstract: Radiation sensitive human cancers are treated with combined interferon and radiation therapy.

Abstract: A loose make-up powder container with a brush inserted into a powder reservoir a short distance but not far enough to reach the powder therein. The brush is loaded by inserting the container, then righting it. The amount of powder loaded on the brush is a function of the area of the brush extending into the reservoir.

Abstract: Novel compounds with angiotensin-converting enzyme inhibitory activity are disclosed. Such compounds are useful in the treatment of cardiovascular disorders, especially hypertension and congestive heart failure, and are useful in the treatment of glaucoma. Also disclosed is a novel process for preparing intermediates useful in the preparation of the claimed compounds.

Abstract: A multistep process is disclosed for preparing azetidinone intermediates used in the making penems and carbapenems wherein intermediates containing ##STR1## R' is independently hydrogen or 1, 2 or 3 of lower alkyl or lower alkoxy, preferably hydrogen, wherein R" is methyl, ethyl, a phenyl or alkyl, preferably ethyl, as a readily removable nitrogen protecting group are made.

Abstract: Processes for the production of 6-hydroxyethyl-2-substituted thio penem-3-carboxylates are disclosed as well as novel penems.

Abstract: Disclosed is an elegant, stable, self-preserving cream formulation containing mometasone furoate, 9.alpha., 21-dichloro-16.alpha.-methyl-1,4-pregnadiene-11.beta.,17.alpha.-diol-3,20- dione-17-(2'-furoate), useful as a topical anti-inflammatory product.

Abstract: 12,13-Oxo derivatives of 16-membered macrolides such as tylosin and 23-O-demycinosyltylosin useful as antibacterials are disclosed.

Abstract: There are disclosed compositions and methods for treating tumors and viruses in humans by administering a combination of gamma interferon and delta-4 alpha-2 (Bgl II-1)/(Bgl II) alpha-1 hybrid interferon, preferably by injection.

Abstract: There is disclosed antibacterial compounds represented by the formula ##STR1## and pharmaceutically acceptable salts or pharmaceutically acceptable esters thereof,wherein:X represents oxygen, sulfur, ##STR2## wherein R is hydrogen, loweralkyl, acetate or methoxycarbonyl; Y is cis, trans or mixtures thereof and is selected from hydroxy, lower alkoxy, aminocarbamoyloxy, methoxycarbonylamino, lower alkylcarbonyloxy, lower alkylcarbonylamino and loweralkylsulfonylamino; andthe wavy lines indicate cis, trans or mixtures thereof.

Abstract: Novel compounds and compositions which inhibit SRS--A in mammals are disclosed. Methods for preparing said compounds and compositions and methods for their use for treating allergic reactions, inflammation and for reducing the severity of myocardial infarction resulting from heart attack are disclosed.Useful intermediates for preparing said compounds are also disclosed.

Abstract: Novel 1,3-dioxolane compounds useful as antifungal and antiallergy agents and represented by the formula ##STR1## wherein Ar is thienyl, pyridyl, biphenyl, phenyl or phenyl substituted by one or more of halo, nitro, cyano, lower alkyl, lower alkoxy or perhalo(lower)alkyl; Y is CH or N;Q is ##STR2## W is --NR.sub.5 --, --O--, --S(O).sub.n --; X is NO.sub.2, NR.sub.6 R.sub.7 or COR.sub.8 ;R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently hydrogen or lower alkyl; R.sub.5 is hydrogen, lower alkyl or (C.sub.2 -C.sub.6) alkanoyl; R.sub.6 and R.sub.7 are independently hydrogen, lower alkyl, phenyl or phenyl substituted by one or more of halo, perhalo loweralkyl, (C.sub.2 -C.sub.6)alkanoyl lower alkyl, lower alkoxy or 2-loweralkyl-3-oxo-1,2,4-trirazol-4-yl or R.sub.6 and R.sub.7 taken together with the nitrogen atom in NR.sub.6 R.sub.7 form substituted or unsubstituted heterocyclyl, said heterocyclyl substituents being (C.sub.2 -C.sub.

Abstract: A sustained release theophylline containing oral dosage formulation comprising theophylline containing micropellets coated with from about 0.5% to about 2% by weight of a pharmaceutically acceptable water-insoluble film former, preferably ethyl cellulose and having first order release. The formulation is an improvement over theophylline containing micropellets coated with two film formers which have zero order release. The oral dosage formulation has superior non-fasting release and absorption characteristics when compared to the zero order release formulation.

Abstract: An oil-in-water cream or lotion emulsion formulation containing clotrimazole having improved antifungal properties containing various amounts of clotrimazole, petrolatum, cetearyl alcohol, propylene glycol, and ceteth-20, with or without other additional ingredients.

Abstract: A multi-step stereospecific process for preparing (3S,4R,5R)-1-(allyloxycarbonyl)-methyl-3-(1-hydroxyethyl)-4-beta-naphthoxy thiocarbonylthio-2-azetidinones, stereoisomers thereof or hydroxy protected analogs thereof from anhydropenicillin. The azetidinones are intermediates useful for producing penems which are a known group of antibacterial compounds. The process involves protecting the hydroxy group of anhydropenicillin with a readily removable hydroxy protecting group, then converting the resulting compound by ozonolysis followed by reaction with a trialklyl phosphite, then hydrolysis to remove the methylidene group at the 2-position of anhydropenicillin. The resulting compound is converted to the unprotected 4-beta-naphthoxy thiocarbonylthio derivative by reaction with allyl alcohol and HCl followed by reaction with O-2-napththalenylcarbonochloridothioate, or to the protected compound by reaction with silver imidazolate and allyl alcohol followed by reaction with O-2-naphthalenylcarbonochloridothioate.

Abstract: Hydrophobic peptides having antihypertensive activity are disclosed. Also disclosed are pharmaceutical compositions comprising a hydrophobic peptide and a method of treatment of mammalian hypertension comprising administering a hydrophobic peptide to a hypertensive mammal.

Abstract: A compound represented by formula I ##STR1## wherein R is hydrogen, or ##STR2## wherein R.sup.1 is N-acylamino, N-alkylamino, N,N-dialkylamino, N-acyl-N-hydroxylamino, nitroso or the pharmaceutically acceptable salts thereof.